2,2',3,3',4,4'-hexahydroxy-1,1'-biphenyl-6,6'-dimethanol dimethyl ether: potent inhibitor of protein kinase C; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 3568 |
| CHEMBL ID | 437222 |
| CHEMBL ID | 59451 |
| CHEMBL ID | 537897 |
| CHEBI ID | 94660 |
| SCHEMBL ID | 1272421 |
| MeSH ID | M0226681 |
| Synonym |
|---|
| bdbm50043774 |
| 6,6''-bis-methoxymethyl-biphenyl-2,3,4,2'',3'',4''-hexaol |
| BRD-K56064827-001-03-9 |
| BRD-K56064827-001-04-7 |
| BIO2_000388 |
| BIO2_000868 |
| BIOMOLKI2_000071 |
| BIOMOLKI_000067 |
| hbdde |
| NCGC00163390-01 |
| NCGC00163390-02 |
| KBIOGR_000455 |
| KBIO3_000849 |
| KBIO2_003023 |
| KBIO3_000850 |
| KBIOSS_000455 |
| KBIO2_005591 |
| KBIO2_000455 |
| IDI1_002143 |
| BSPBIO_001115 |
| NCGC00163390-03 |
| HMS1990G17 |
| CHEMBL437222 , |
| CHEMBL59451 , |
| CHEMBL537897 , |
| BMK1-G7 |
| 2,2',3,3',4,4'-hexahydroxy-1,1'-biphenyl-6,6'-dimethanol dimethyl ether |
| HMS1362G17 |
| HMS1792G17 |
| 154675-18-0 |
| 5-(methoxymethyl)-4-[2,3,4-trihydroxy-6-(methoxymethyl)phenyl]benzene-1,2,3-triol |
| NCGC00163390-04 |
| hhbpdde |
| [1,1'-biphenyl]-2,2',3,3',4,4'-hexol,6,6'-bis(methoxymethyl)- |
| CCG-100671 |
| bdbm50375658 |
| bdbm50375660 |
| SCHEMBL1272421 |
| HMS3403G17 |
| AKOS030533055 |
| CHEBI:94660 |
| J-009130 |
| Q27166474 |
| hbdde - cas 154675-18-0 |
| DTXSID20935042 |
| 6,6'-bis(methoxymethyl)[1,1'-biphenyl]-2,2',3,3',4,4'-hexol |
| HY-131305 |
| CS-0132740 |
| Class | Description |
|---|---|
| tannin | Any of a group of astringent polyphenolic vegetable principles or compounds, chiefly complex glucosides of catechol and pyrogallol. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 0.2701 | 0.0032 | 45.4673 | 12,589.2998 | AID2517; AID2572 |
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 0.1074 | 0.0040 | 23.8416 | 100.0000 | AID485290 |
| Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 3.9716 | 0.1409 | 11.1940 | 39.8107 | AID2451 |
| Chain A, ATP-DEPENDENT DNA HELICASE Q1 | Homo sapiens (human) | Potency | 1.0000 | 0.1259 | 19.1169 | 125.8920 | AID2549 |
| endonuclease IV | Escherichia coli | Potency | 4.4668 | 0.7079 | 12.4324 | 31.6228 | AID2565 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 14.1254 | 0.1000 | 20.8793 | 79.4328 | AID588453 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 10.2663 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
| TDP1 protein | Homo sapiens (human) | Potency | 4.7394 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 4.7359 | 0.1800 | 13.5574 | 39.8107 | AID1460; AID1468 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 25.1189 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 0.0336 | 0.5318 | 15.4358 | 37.6858 | AID504845 |
| 67.9K protein | Vaccinia virus | Potency | 11.2202 | 0.0001 | 8.4406 | 100.0000 | AID720579 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 1.0000 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| runt-related transcription factor 1 isoform AML1b | Homo sapiens (human) | Potency | 1.4348 | 0.0200 | 7.9858 | 39.8107 | AID504374; AID504375 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 17.9008 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| core-binding factor subunit beta isoform 2 | Homo sapiens (human) | Potency | 1.4348 | 0.0200 | 7.9858 | 39.8107 | AID504374; AID504375 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 1.5849 | 0.1337 | 25.4129 | 89.1251 | AID588795 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 2.8184 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 0.4408 | 0.0316 | 22.3146 | 100.0000 | AID588579 |
| Glutamate receptor 1 | Rattus norvegicus (Norway rat) | Potency | 0.3162 | 0.0141 | 8.6024 | 39.8107 | AID2572 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 0.3162 | 0.0015 | 51.7393 | 15,848.9004 | AID2572 |
| Glutamate receptor 3 | Rattus norvegicus (Norway rat) | Potency | 0.3162 | 0.0141 | 8.6024 | 39.8107 | AID2572 |
| Glutamate receptor 4 | Rattus norvegicus (Norway rat) | Potency | 0.3162 | 0.0141 | 8.6024 | 39.8107 | AID2572 |
| C-terminal-binding protein 1 | Homo sapiens (human) | Potency | 6.7467 | 0.3014 | 9.3210 | 19.0148 | AID720541 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Protein kinase C gamma type | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 0.0001 | 1.0354 | 10.0000 | AID163878 |
| Protein kinase C alpha type | Rattus norvegicus (Norway rat) | IC50 (µMol) | 98.0000 | 0.0000 | 0.2193 | 1.0000 | AID165112 |
| Protein kinase C delta type | Rattus norvegicus (Norway rat) | IC50 (µMol) | 98.0000 | 0.0000 | 0.2585 | 1.0000 | AID165112 |
| Protein kinase C epsilon type | Rattus norvegicus (Norway rat) | IC50 (µMol) | 98.0000 | 0.0000 | 0.2585 | 1.0000 | AID165112 |
| Protein kinase C zeta type | Rattus norvegicus (Norway rat) | IC50 (µMol) | 98.0000 | 0.0000 | 0.2585 | 1.0000 | AID165112 |
| Protein kinase C alpha type | Homo sapiens (human) | IC50 (µMol) | 43.0000 | 0.0001 | 0.9720 | 10.0000 | AID163163 |
| Protein kinase C gamma type | Rattus norvegicus (Norway rat) | IC50 (µMol) | 98.0000 | 0.0000 | 0.2640 | 1.1000 | AID165112 |
| Protein kinase C beta type | Rattus norvegicus (Norway rat) | IC50 (µMol) | 98.0000 | 0.0000 | 0.2164 | 1.1000 | AID165112 |
| Protein kinase C eta type | Rattus norvegicus (Norway rat) | IC50 (µMol) | 98.0000 | 0.0000 | 0.2585 | 1.0000 | AID165112 |
| Protein kinase C theta type | Rattus norvegicus (Norway rat) | IC50 (µMol) | 98.0000 | 0.0000 | 0.2585 | 1.0000 | AID165112 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID165112 | Inhibitory activity against protein kinase C of rat brain | 1994 | Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1 | New hexahydroxybiphenyl derivatives as inhibitors of protein kinase C. |
| AID163163 | Inhibition of protein kinase C alpha | 1994 | Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1 | New hexahydroxybiphenyl derivatives as inhibitors of protein kinase C. |
| AID163878 | Inhibition of protein kinase C gamma | 1994 | Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1 | New hexahydroxybiphenyl derivatives as inhibitors of protein kinase C. |
| AID219159 | Inhibition of c-AMP dependent kinase (PKA) catalytic subunit | 1994 | Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1 | New hexahydroxybiphenyl derivatives as inhibitors of protein kinase C. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.58) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||